

ACCESS TO DIRECT ACTING ANTIVIRAL THERAPY FOR RECIPIENTS OF SOLID ORGANS FROM HEPATITIS C-VIREMIC DONORS

CORI EDMONDS, PHARM D | ALICIA CARVER, PHARM D | JOSH DECLERCQ, MS | LEENA CHOI, PH D | MEGAN PETER, PH D | RACHEL FORBES, MD | BEATRICE CONCEPCION, MD | KELLY SCHLENDORF, MD | ROMAN PERRI, MD

INTRODUCTION

Medications to treat the hepatitis C virus (HCV) are notoriously expensive and plagued by strict insurance prior authorization (PA) criteria. Emerging data supports transplantation of organs from viremic, HCV-positive donors into HCV-negative recipients to expand the donor pool.^{1,2} However, when implemented as standard practice post solid organ transplantation (SOT), prescription (Rx) access to HCV direct acting antivirals (DAAs) to treat patients who develop donor-derived hepatitis C (dd-HCV) has not been well described.

References:
1. Schlendorf KH, Zalawadiya S, Shah Ashish, et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. *J Heart Lung Transplant*. 2018; 37:763-769.
2. Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. *J Am Soc Nephrol*. 2019;30:1929-1951.

Disclosures: Authors of this study have no relevant financial or non-financial interests to disclose

PURPOSE

Evaluate HCV DAA prescription access, cost, timing and barriers to first dose (FD) in solid organ transplant recipients with confirmed, active dd-HCV infection post transplantation in a real-world, standard practice.

METHODS

DESIGN	Single center, IRB approved, retrospective cohort review
SAMPLE	dd-HCV solid organ transplant recipients transplanted between October 2016 and May 2019 prescribed HCV DAA therapy at Vanderbilt University Medical Center
OUTCOMES and VARIABLES	HCV DAA insurance approval rates Insurance PA denial reasons Time to FD Barriers encountered from BI to FD Predictors of delay from BI to FD Copay assistance use Out-of-pocket (OOP) DAA cost
ANALYSIS	Descriptive statistics to summarize data. Univariate proportional odds logistic regression to assess factors related to time from BI to FD.

Cohort Characteristics (n=91)

	M [SD] or % (n)
Age (Years)	55 [11]
Gender (Male)	68 (62)
Race (White)	72.5 (66)
Genotype	
1	69 (63)
2	8 (7)
3	22 (20)
Mixed	1 (1)
Transplant Type	
Heart	52 (47)
Kidney	30 (27)
Liver	11 (10)
Heart/Kidney	4 (4)
Liver/Kidney	1 (1)
Lung	2 (2)

Insurance Type	
Government	46 (42)
Private/Commercial	54 (49)

Prescription Coverage	
Insured	97 (88)
Not Insured	2 (2)
Underinsured	1 (1)

Specialty Pharmacy Rx Dispense Site	
On-Site (VSP)	69 (63)
Off-Site (Non-VSP)	31 (28)


HCV DAA Prescribed (12 weeks)	
Sofosbuvir/Ledipasvir	46 (42)
Sofosbuvir/Velpatasvir	13 (12)
Glecaprevir/Pibrentasvir	41 (37)

Pre-Therapy HCV Viral Load	
< 1 million	48 (44)
1 to < 25 million	26 (24)
≥ 25 million	23 (23)


Therapy Response Rate	
Sustained Viral Response	98 (89)
Relapsed	1 (1)
Therapy not completed	1 (1)

RESULTS


HCV DAA Access Rates	
Prescription Insurance Status	% (n)
Rx Insurance Approvals	100 (88)
PAP (no Rx insurance) Approvals	100 (3)



HCV DAA Access Timeline		
Time Period	Median Days	IQR
SOT to FD	45	[34 - 66]
SOT to BI	28	[18.5 - 41.5]
BI to FD	16	[9 - 27]
BI to Approval	6	[4 - 12]
Approval to FD	8	[5 - 12.5]




Barriers and Delays to First Dose



- In univariate analyses, time between BI and FD was significantly longer for patients who:
 - Filled their first Rx at an off-site specialty pharmacy
 - Required an insurance appeal
 - Held private/commercial insurance
 - Received a non-kidney solid organ transplant
- A third of patients (n=33, 36%) encountered a delay between BI to FD that was not related to a PA denial:
 - BI to Approval Period (n=9, 27%)
 - Missing clinical data for PA (n=4)
 - Delay in obtaining PA form (n=3)
 - PAP paperwork process delay (n=2)
 - Approval to FD Period (n=24, 71%)
 - Awaiting inpatient setting discharge (n=11)
 - Pharmacy Rx processing/shipping issue (n=9)
 - Patient/Provider request (n=2)
 - Insurance changed between Approval to FD (n=2).

HCV DAA Therapy Access Standard Process



HCV DAA Rx Cost

Copay Assistance Required*		
	Yes	No
	49% (n=31)	51% (n=32)
Mean OOP Cost		
Pre-Assistance	\$2,003 [Range: \$7-\$7,536]	\$8 [Range: \$0-\$100]
Post-Assistance	\$2 [Range: \$0-\$5]	Not Applicable

* On-Site Pharmacy (VSP) Data Only

CONCLUSIONS

- HCV DAA therapy for dd-HCV solid organ transplant patients is achievable and affordable in the outpatient setting.
- Use of an on-site specialty pharmacy for the first Rx fill is associated with a significantly shorter time to FD.
- Delays to FD after referral for BI/PA initiation are more likely when insurance requires use an off-site specialty pharmacy to fill the prescription, coverage is with private insurance, SOT was non-kidney, and an insurance appeal after initial PA denial is required.